



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/980,265	03/22/2002	Monique Bachy	01-1702	9818

20306 7590 03/09/2006

MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 S. WACKER DRIVE
32ND FLOOR
CHICAGO, IL 60606

EXAMINER

GIBBS, TERRA C

ART UNIT	PAPER NUMBER
----------	--------------

1635

DATE MAILED: 03/09/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

09/980,265 3/22/02 Bachy et al.

01-1702

EXAMINER

Terra C. Gibbs

ART UNIT	PAPER
----------	-------

1635

332006

DATE MAILED:


Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents**37 CFR 1.105 Request**

Applicant's reply filed December 13, 2005 is acknowledged. It is noted that in the Office Action mailed April 23, 2003, the Specification was objected to because it made reference to Figures 1-11 where no Figures have been filed with the instant application. In response to this objection, Applicants amended the Specification and deleted any reference to Figures in the disclosure. In doing this, Applicants have deleted information necessary to properly examine the instant claims. For example, page 13, lines 9-17 has been amended to recite, "The results obtained for each of the oligonucleotides tested show that all the nucleotides according to the invention have a result which is clearly greater than the result obtained with the medium alone or the negative control A15(S), which means that they are all capable of stimulating lymphocyte proliferation". Similarly, page 15, lines 16-23 has been amended to recite, "The results show that all the oligonucleotides according to the invention are capable of inducing lymphocyte proliferation and that particularly good results are obtained when the sequences of the oligonucleotides are those identified by SEQ IDs: 9 to 12".

The Examiner cannot properly examine the instant claims without the pertinent information provided in Figures 1-11. As required under 37 CFR 1.105, Applicants are required to provide information that would aid in the examination of the application, said information being Figures 1-11. Applicant is reminded that a reply, or a failure to reply, to a requirement for information under this section will be governed by §§ 1.135 and 1.136.

Since the above-mentioned reply appears to be bona fide, Applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).


ANDREW WANG
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

tcg
March 3, 2006